Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | MMP2 | P08253 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18262000 | 1.00 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL1757034 | 1.00 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL78650 | 1.00 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL28098897 | 0.97 | EPHX1 (0.61) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL966688 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL27740151 | 0.95 | EPHX1 (0.56) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| Urea SCHEMBL28834423 | 0.95 | EPHX1 (0.56) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL688635 | 0.92 | — | — | |
| SCHEMBL15277766 | 0.91 | EPHX1 (0.74) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27565992 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043261-A1 | AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME | 日本化薬株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11891348-B2 | Cycloheptylamine derivatives as anti-diabetic agents | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2024-02-06 | — | — | US | disclosed |
| CN-114026199-B | Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| EP-3735404-B1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | SEAL ROCK THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11713290-B2 | Cycloheptylamine derivatives as anti-diabetic agents | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2023-08-01 | — | — | US | disclosed |
| US-20230019461-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-110945083-B | Styrene compound or salt thereof, polarizing film, polarizing plate and display device | 日本化药株式会社 | 2022-07-01 | — | — | CN | disclosed |
| EP-3998502-A1 | POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE | Nippon Kayaku Kabushiki Kaisha (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-20210355074-A1 | CYCLOHEPTYLAMINE DERIVATIVES AS ANTI-DIABETIC AGENTS | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2021-11-18 | — | — | US | disclosed |
| US-20210347725-A1 | CYCLOHEPTYLAMINE DERIVATIVES AS ANTI-DIABETIC AGENTS | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2021-11-11 | — | — | US | disclosed |
| EP-0474561-A1 | Arylalkylamines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-03-11 | — | — | EP | disclosed |
| EP-0428434-A2 | Compounds of aromatic amines and their enantiomers, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1991-05-22 | — | — | EP | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
| US-4391980-A | FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0007605-B1 | A PROCESS FOR INVERTING THE CONFIGURATION IN OPTICALLY ACTIVE COMPOUNDS AND OPTICALLY ACTIVE INTERMEDIATE COMPOUNDS AND THEIR SALTS REQUIRED THEREFOR | CIBA-GEIGY AG (CH) | 1982-09-15 | — | — | EP | disclosed |
| US-4294966-A | SALT FORMATION | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713290-B2 | Cycloheptylamine derivatives as anti-diabetic agents | BHMT2, BHMT, GPR119 | EPHX1 2514/4885NPC1 2026/4885SMN1; SMN2 1441/4885 |
| US-11891348-B2 | Cycloheptylamine derivatives as anti-diabetic agents | BHMT2, BHMT, GPR119 | EPHX1 2514/4885NPC1 2026/4885SMN1; SMN2 1441/4885 |
| US-20210355074-A1 | CYCLOHEPTYLAMINE DERIVATIVES AS ANTI-DIABETIC AGENTS | BHMT2, BHMT, GPR119 | EPHX1 2514/4885NPC1 2026/4885SMN1; SMN2 1441/4885 |
| US-20210347725-A1 | CYCLOHEPTYLAMINE DERIVATIVES AS ANTI-DIABETIC AGENTS | BHMT2, BHMT, GPR119 | EPHX1 2514/4885NPC1 2026/4885SMN1; SMN2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.